This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Stelazine

GlaxoSmithKline plc

Drug Names(s): Trifluoperazine

Description: Stelazine is a typical or first generation antipsychotic. It blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain (in the ventral striatum); depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

Regarding antipsychotic/antianxiety effects, observations suggest that Stelazine's primary action is to depress the physiologic accompaniments of the emotional factors of the personality which are believed to be basically evoked by the limbic system and its connections with the hypothalamus. Evidence indicates that the phenothiazines like Stelazine act on the subcortical areas of the CNS which influence the affective functions. Stelazine is specific in its activity and its effects seem limited to parts of the basal ganglia, such as the amygdaloid nucleus.

In terms of antiemetic effects, Stelazine inhibits indirect stimulation of the vomiting center, but does not inhibit indirect stimulation of the center by gastrointestinal stimulants. Because of this, it is believed that its site of action is the chemoreceptor trigger zone.


Stelazine News

Pink Sheet SK&F's Stelazine

Pink Sheet Nova


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug